Pharma cos. get Bystolic generic delay claims tossed

White & Case is mentioned in Law360 for securing a dismissal of all claims brought by direct and indirect purchasers in class-action and opt-out complaints against AbbVie and other pharmaceutical firms.  White & Case partner Eric Grannon presented oral argument on the motion in December 2021 on behalf of all Defendants. 

Plaintiffs had alleged that Defendants conspired to delay competition for generic forms of hypertension drug Bystolic by entering into reverse payment agreements under FTC v. Actavis.

AbbVie is represented by White & Case lawyers J. Mark Gidley, Eric Grannon, Peter Carney, Adam Acosta, Celia McLaughlin, Holly Letourneau, and Kelly Newman.

See the full article here 

Press contact
For more information please speak to your local media contact.